ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

OPTN OptiNose Inc

0,8776
0,00 (0,00%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
OptiNose Inc OPTN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 0,8776 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,8776
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202413:00GLOBEOptinose Provides Corporate Update on XHANCE Launch and..
04.4.202422:01GLOBEOptinose to Present at the Needham Virtual Healthcare..
15.3.202420:34GLOBEXHANCE Approved by FDA as First and Only Medication..
08.3.202422:10EDGAR2Form 8-K - Current report
07.3.202422:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
07.3.202413:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07.3.202413:00GLOBEOptinose Reports Fourth Quarter and Full Year 2023 Financial..
07.3.202413:00EDGAR2Form 8-K - Current report
29.2.202422:40GLOBEOptinose Announces Reporting Date for Fourth Quarter 2023..
29.2.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202413:08EDGAR2Form 8-K - Current report
22.2.202422:28EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15.2.202402:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202423:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202420:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18.1.202418:00GLOBEOptinose Announces the Publication of ReOpen Phase 3..
21.12.202322:11EDGAR2Form 8-K - Current report
20.12.202318:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202318:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202314:48DJNOptinose Shares Slide Premarket as FDA Extends Xhance Review
06.12.202313:02EDGAR2Form 8-K - Current report
06.12.202313:00GLOBEOptinose Announces 3-Month Extension of FDA Review Period..
22.11.202315:00GLOBEOptinose to Present at the 35th Annual Piper Sandler..
09.11.202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202313:02EDGAR2Form 8-K - Current report
09.11.202313:00GLOBEOptinose Reports Third Quarter 2023 Financial Results and..
27.10.202314:00GLOBEOptinose Announces Reporting Date for Third Quarter 2023..
22.9.202315:01GLOBEOptinose to Present at the 2023 Cantor Global Healthcare..
20.9.202301:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.9.202301:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.8.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
10.8.202322:05EDGAR2Form S-3 - Registration statement under Securities Act of..
10.8.202313:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202313:02EDGAR2Form 8-K - Current report
10.8.202313:00GLOBEOptinose Reports Second Quarter 2023 Financial Results and..
27.7.202313:27EDGAR2Form 8-K - Current report
27.7.202313:00GLOBEOptinose Announces Preliminary Second Quarter 2023 XHANCE..
16.6.202322:08GLOBEOptinose Announces Inducement Grant Under Nasdaq Listing..
02.6.202319:00GLOBEOptinose to Present at the Jefferies Healthcare Conference
11.5.202313:00GLOBEOptinose Reports First Quarter 2023 Financial Results and..
04.5.202313:00GLOBEOptinose Announces FDA Acceptance of Supplemental New Drug..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock